Indeed, we have previously shown that a shift from glycolysis to anaplerotic mitochondrial metabolism occurs following response to vemurafenib in BRAF-mutant melanoma cells, improving survival in nutrient-depleted conditions, potentially facilitating the emergence of drug resistant clones.19 Here we show that under low glucose conditions (1 mM) and in the absence of glutamine and pyruvate, resistant cells are able to proliferate better than the sensitive clone. The gene discussed is BRAF; the disease is melanoma.